- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Long acting injectable form of aripiprazole for schizophrenia
- Meeting Date: December 2024
- Public Summary Document (PSD) December 2024 PBAC Meeting – (PDF 698KB)
- Public Summary Document (PSD) December 2024 PBAC Meeting – (Word 185KB)
Aripiprazole – December 2024
Aripiprazole: I.M. injection (modified release) 720 mg in 2.4 mL pre-filled syringe, I.M. injection (modified release) 960 mg in 3.2 mL pre-filled syringe; Abilify Asimtufii® – December 2024
Last updated
30 May 2025